DK2806883T3 - Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation - Google Patents

Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation Download PDF

Info

Publication number
DK2806883T3
DK2806883T3 DK13706770.8T DK13706770T DK2806883T3 DK 2806883 T3 DK2806883 T3 DK 2806883T3 DK 13706770 T DK13706770 T DK 13706770T DK 2806883 T3 DK2806883 T3 DK 2806883T3
Authority
DK
Denmark
Prior art keywords
immunomodulation
biomarkers
combination therapies
oncolytic virus
oncolytic
Prior art date
Application number
DK13706770.8T
Other languages
English (en)
Inventor
Frank Tufaro
Juan Fueyo-Margareto
Frederick Lang
Candelaria Gomez-Manzano
W K Alfred Yung
Amy Heimberger
Charles Conrad
Original Assignee
Dnatrix Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnatrix Inc, Univ Texas filed Critical Dnatrix Inc
Application granted granted Critical
Publication of DK2806883T3 publication Critical patent/DK2806883T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
DK13706770.8T 2012-01-25 2013-01-25 Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation DK2806883T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590441P 2012-01-25 2012-01-25
US201261637191P 2012-04-23 2012-04-23
PCT/US2013/023304 WO2013112942A1 (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation

Publications (1)

Publication Number Publication Date
DK2806883T3 true DK2806883T3 (da) 2019-07-22

Family

ID=47754947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13706770.8T DK2806883T3 (da) 2012-01-25 2013-01-25 Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation

Country Status (12)

Country Link
US (3) US10238698B2 (da)
EP (2) EP2806883B1 (da)
JP (3) JP2015508156A (da)
KR (1) KR102081567B1 (da)
CN (1) CN104427992B (da)
AU (2) AU2013211871B2 (da)
BR (1) BR112014018331A8 (da)
CA (1) CA2862390A1 (da)
DK (1) DK2806883T3 (da)
HK (2) HK1204577A1 (da)
SG (3) SG10201913784YA (da)
WO (1) WO2013112942A1 (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2251034T (pt) 2005-12-02 2018-05-22 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
ES2759785T3 (es) 2012-02-02 2020-05-12 Univ Texas Adenovirus que expresan antígenos oncógenos heterólogos
WO2013131050A1 (en) * 2012-03-02 2013-09-06 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for differential treatment of cancer
US20150118244A1 (en) * 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
WO2014036412A2 (en) * 2012-08-30 2014-03-06 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
BR112015021414B1 (pt) 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
WO2014186761A2 (en) * 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
CN104415335A (zh) * 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
CN114317461A (zh) * 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
WO2015127501A1 (en) * 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
AU2015267008A1 (en) * 2014-05-28 2017-01-05 Dana-Farber Cancer Institute, Inc. Activating JAK kinase biomarkers predictive of anti-immune checkpoint inhibitor response
EP3209382B1 (en) * 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
US11060150B2 (en) 2015-03-17 2021-07-13 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating cancer
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
WO2016196765A2 (en) * 2015-06-03 2016-12-08 Aelan Cell Technologies, Inc. Companion methods and kits for il-2-based therapies and mesenchymal stem cell-based therapies
WO2017013421A1 (en) 2015-07-20 2017-01-26 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
WO2017014296A1 (ja) * 2015-07-22 2017-01-26 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
KR102201147B1 (ko) 2015-08-11 2021-01-11 카리디 바이오테라퓨틱스, 인크. 암 치료에 사용하기 위한 천연두 백신
JP7332293B2 (ja) 2015-09-04 2023-08-23 アスラン ファーマシューティカルズ ピーティーイー リミテッド バルリチニブおよび抗癌剤を含んでなる併用療法
WO2017062615A2 (en) * 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
JP6850290B2 (ja) * 2015-10-15 2021-03-31 デューク ユニバーシティー 併用療法
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
CN116063542A (zh) 2015-12-02 2023-05-05 阿吉纳斯公司 抗体和其使用方法
US10570377B2 (en) * 2016-01-08 2020-02-25 Replimune Limited Oncolytic virus strain
EP3193173A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Serological autoantibodies as biomarker for colorectal cancer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE
EP4070812A1 (en) * 2016-01-21 2022-10-12 The Board of Trustees of the Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
CN105603085B (zh) * 2016-01-29 2019-01-29 北京泱深生物信息技术有限公司 椎间盘退行性病变的诊治靶标
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN114028549A (zh) * 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
US11497781B2 (en) * 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017176289A1 (en) * 2016-04-08 2017-10-12 Celgene Corporation Uses of lenalidomide and car t-cells
GB201608918D0 (en) * 2016-05-20 2016-07-06 Aslan Pharmaceuticals Pte Ltd Method
CN109789177A (zh) * 2016-05-27 2019-05-21 德那翠丝有限公司 腺病毒和免疫调节剂组合治疗
US11865149B2 (en) 2016-06-17 2024-01-09 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
RU2758007C2 (ru) 2016-06-30 2021-10-25 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
WO2018071824A1 (en) * 2016-10-13 2018-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
WO2018085461A1 (en) 2016-11-01 2018-05-11 Dnatrix, Inc. Combination therapy for treatment of brain cancers
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CN110381997A (zh) * 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
AU2017379835A1 (en) 2016-12-21 2019-07-11 Dnatrix Armed replication-competent oncolytic adenoviruses
WO2018132571A1 (en) * 2017-01-13 2018-07-19 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
CN108338994A (zh) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
CA3052987A1 (en) * 2017-02-08 2018-08-16 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
WO2018152095A1 (en) * 2017-02-14 2018-08-23 Celgene Corporation Treatment of cancer with smg1-inhibitors
JP2020516590A (ja) 2017-04-14 2020-06-11 コールド ジェネシス， インコーポレイテッド 膀胱癌の治療方法
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
WO2019143585A1 (en) * 2018-01-17 2019-07-25 Eli Lilly And Company Compounds and methods targeting interleukin-19
CN108414660B (zh) * 2018-03-08 2020-03-20 中国药科大学 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
KR102091567B1 (ko) * 2018-06-15 2020-03-20 인하대학교 산학협력단 오스테오폰틴 단백질 단편을 유효성분으로 함유하는 뇌손상 예방 또는 치료용 약학 조성물
CN110755619A (zh) * 2018-07-27 2020-02-07 复旦大学 一种人疱疹病毒裂解复制激活的宿主标志物及其用途
CN108998529A (zh) * 2018-08-30 2018-12-14 上海交通大学医学院附属上海儿童医学中心 肺腺癌检测试剂盒及检测tulp2基因甲基化水平的方法
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
EP3876951A1 (en) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
US20220170940A1 (en) * 2019-03-27 2022-06-02 Singapore Health Services Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis
EP3946421A4 (en) * 2019-03-28 2022-12-21 Mayo Foundation for Medical Education and Research IFNBETA AS A PHARMACODYNAMIC MARKER IN ONCOLYTIC THERAPY VSV-IFNBETA-NIS
KR102199141B1 (ko) * 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
CN110687281B (zh) * 2019-08-26 2023-05-23 中国医学科学院肿瘤医院 Pd-l1自身抗体在肿瘤预后评估中的应用
CN114630683A (zh) * 2019-08-29 2022-06-14 拜耳诺克斯有限公司 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物
WO2021061775A1 (en) * 2019-09-23 2021-04-01 Sillajen, Inc. Immune assay for monitoring response to oncolytic vaccinia virus and uses thereof
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
EP4105943A4 (en) * 2020-05-08 2024-03-20 Lunit Inc. METHOD AND SYSTEM FOR PREDICTING RESPONSE TO AN IMMUNONONCOLOGICAL AGENT
WO2021225421A1 (ko) * 2020-05-08 2021-11-11 주식회사 루닛 면역 항암제에 대한 반응을 예측하는 방법 및 시스템
JP2023525465A (ja) * 2020-05-08 2023-06-16 ルニット インコーポレイテッド 病理スライドイメージに対する免疫表現型と関連付けられた情報を提供する方法及び装置
CN111579788A (zh) * 2020-05-29 2020-08-25 郑州大学 一种高灵敏肿瘤标志物EPHA2的Simoa试剂盒及其应用
AU2021324483A1 (en) 2020-08-10 2023-04-13 Mesoblast International Sàrl Cellular compositions and methods of treatment
CN112345755B (zh) * 2020-09-23 2023-06-16 杭州凯保罗生物科技有限公司 乳腺癌的生物标志物及其应用
JP2024500575A (ja) * 2020-12-22 2024-01-09 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド がんの早期かつ正確な検出のための、血液ベースのタンパク質バイオマーカーパネル
WO2023107878A1 (en) * 2021-12-06 2023-06-15 Oncorus, Inc. Compositions and methods of seneca valley virus (svv) related cancer therapy
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
JPH10509880A (ja) 1994-11-28 1998-09-29 ジェネティック セラピー， インコーポレイテッド 組織特異的複製のためのベクター
CA2218610A1 (en) 1995-04-17 1996-10-24 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6080578A (en) 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
WO1998039467A2 (en) 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US6096718A (en) 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
EP1131458A1 (en) 1998-11-18 2001-09-12 CANJI, Inc. Viral vectors with late transgene expression
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
EP1180932B1 (en) 1999-05-12 2012-01-11 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
AU6120600A (en) 1999-06-08 2000-12-28 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
AU1190901A (en) 1999-09-30 2001-04-30 Trustees Of The University Of Pennsylvania, The Replication selective adenoviruses for use in cancer therapy
WO2001028569A1 (en) 1999-10-15 2001-04-26 Canji, Inc. Targeted vectors
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US20070134202A1 (en) * 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
CA2563103C (en) 2004-03-31 2015-02-17 Tomoki Todo Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
WO2006005185A1 (en) 2004-07-13 2006-01-19 The University Of British Columbia Indoleamine 2,3-dioxygenase (ido) inhibitors
EP2650020B1 (en) 2005-05-06 2016-08-24 Providence Health & Services - Oregon Trimeric OX40-immunoglobulin fusion protein and methods of use
SI1907424T1 (sl) * 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
MX2008002743A (es) 2005-08-31 2008-03-26 Oncolytics Biotech Inc Potenciacion in vivo del reconocimiento de neoplasmas por el sistema inmunitario posterior a viroterapia oncolitica o vector para terapia genica.
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
RS54233B1 (en) * 2008-08-25 2015-12-31 Amplimmune Inc. PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
SI2379586T1 (sl) * 2008-12-22 2017-02-28 Targovax Oy Onkolitični adenovirusni vektorji in z njimi povezani postopki in uporabe
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
EP2995315B1 (en) 2009-05-15 2023-12-27 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
EP3375791A1 (en) * 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Combination immunotherapy for the treatment of cancer
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
EP2407177A1 (en) 2010-07-13 2012-01-18 Institut Gustave Roussy Adenovirus vaccine vectors
EP2383577A1 (en) * 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
ES2759785T3 (es) 2012-02-02 2020-05-12 Univ Texas Adenovirus que expresan antígenos oncógenos heterólogos
SG10201710528WA (en) 2013-06-18 2018-01-30 Dnatrix Inc Treatment of brain cancer with oncolytic adenovirus

Also Published As

Publication number Publication date
US20140377221A1 (en) 2014-12-25
BR112014018331A2 (da) 2017-06-20
US11065285B2 (en) 2021-07-20
KR20150008846A (ko) 2015-01-23
JP2019066482A (ja) 2019-04-25
KR102081567B1 (ko) 2020-02-26
EP3578198A1 (en) 2019-12-11
AU2013211871A1 (en) 2014-08-14
HK1204577A1 (en) 2015-11-27
CN104427992A (zh) 2015-03-18
US20190269744A1 (en) 2019-09-05
US20200330533A1 (en) 2020-10-22
AU2018201776A1 (en) 2018-04-05
US10238698B2 (en) 2019-03-26
CA2862390A1 (en) 2013-08-01
SG10201913784YA (en) 2020-03-30
JP2015508156A (ja) 2015-03-16
SG11201404313YA (en) 2014-10-30
BR112014018331A8 (pt) 2017-07-11
CN104427992B (zh) 2017-12-19
EP2806883B1 (en) 2019-04-24
HK1208349A1 (en) 2016-03-04
SG10201604654RA (en) 2016-07-28
JP2021103174A (ja) 2021-07-15
WO2013112942A1 (en) 2013-08-01
AU2013211871B2 (en) 2017-12-14
EP2806883A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
DK2806883T3 (da) Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
HK1211851A1 (en) Anti-dengue virus antibodies and uses thereof
DK3199552T3 (da) Anti-ceacam5-antistoffer og anvendelser heraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2855736T3 (da) Elektrolysator og energisystem
DK2850202T3 (da) Fremgangsmåder og grupper
DK2877832T3 (da) System til mikrofluidisk orientering og sortering af partikler
DK2838917T3 (da) Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK3254703T3 (da) Adeno-associerede virusvirioner med variant capsid og fremgangsmåder til anvendelse deraf
DK2801139T3 (da) Fremgangsmåde og apparat til styring af frekvensomformer
DK3293183T3 (da) Hæmmerforbindelser
BR112014031384A2 (pt) métodos e sistemas
CO6870031A2 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
DE112013004614T8 (de) Gestentastatur mit Gestenannullierung
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK2805670T3 (da) Forbedringer af og i sammenhæng med oftalmoskoper
FI20116089L (fi) Järjestely ja laite
GB201321144D0 (en) Improved oncolytic viruses
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
GB201306147D0 (en) Novel biomarker signature and uses thereof
EP3005827A4 (en) Viral molecular network architecture and design
DK2854928T3 (da) Multilumenkateter med forbedrede strømningsegenskaber
FI20136192A (fi) Pakokaasupesuri ja laiva